US · Healthcare · Medical Care Facilities
EPS came in at 1.52 against a street estimate of 1.37 — a beat of 10.9%.
Analysts rate Encompass Health Corp a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $156.08.
CONFIDENT Encompass Health delivered strong Q3 growth, raised 2026 guidance, and sees durable demand from acuity, VA, capacity expansion, and demographic tailwinds. Temporary bad-debt disruption should normalize, while Florida supplemental payments remain uncertain. Q3 FY26 Florida’s fiscal 2026 Medicaid directed-payment program remains pending CMS approval. North Carolina’s certificate-of-need repeal became effective October 1, with 15 prioritized markets and six parcels under contract. Analysts focused on 2027 earnings drivers, capacity constraints, RCD expansion, bad debt, acuity, and capital allocation. Management emphasized durable demand and operational opportunities while flagging Florida payment and RCD-processing uncertainty. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.67% |
| T. Rowe Price Associates, Inc. | 5.14% |
| Vanguard Portfolio Management, LLC | 5.01% |
| Vanguard Capital Management, LLC | 4.55% |
| Wellington Management Company LLP | 3.34% |
| State Street Corp | 3.24% |
| Citadel Advisors Llc | 2.61% |
| AllianceBernstein L.P. | 2.51% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net operating revenues were $1,609.5 million, up from $1,477.5 million in the third quarter of 2025. • Third-q | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net operating revenue rose 8.9% to $1,609.5 million from $1,477.5 million. • Diluted income from continuing operations pe | 2026-10-28 |
| Company announcement · Q3 2026 ENCOMPASS HEALTH CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued $100 million in aggregate principal amount of 5.875% Senior Notes | 2026-08-13 |
| Quarterly report · Q2 2026 ENCOMPASS HEALTH CORPORATION – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Operating Revenues (Q2 2026): $1,597.4 million vs. $1,457.7 million | 2026-08-07 |
| Results announced · Q3 2026 ENCOMPASS HEALTH Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net operating revenue Q2 2026: $1,597.4 million, up 9.6% from $1,457.7 million in Q2 20 | 2026-08-05 |
| Material agreement · Q2 2026 ENCOMPASS HEALTH CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Issued $500 million in aggregate principal amount of 5.875% Senior Notes due June | 2026-06-01 |
| Material agreement · Q2 2026 ENCOMPASS HEALTH CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issuing $500 million in aggregate principal amount of 5.875% senior notes | 2026-05-15 |
| Quarterly report · Q1 2026 ENCOMPASS HEALTH CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net operating revenues: $1,586.6 million (Q1 2026) vs. $1,455.4 million (Q1 2 | 2026-05-01 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.21 / share ex-date Jan 4, 2027 · pay Jan 15, 2027 | 2027-01-04 |
| Dividend | $0.21 / share ex-date Oct 1, 2026 · pay Oct 15, 2026 | 2026-10-01 |
| Dividend | $0.19 / share ex-date Jul 1, 2026 · pay Jul 15, 2026 | 2026-07-01 |
| Dividend | $0.19 / share ex-date Apr 1, 2026 · pay Apr 15, 2026 | 2026-04-01 |
| Dividend | $0.19 / share ex-date Jan 2, 2026 · pay Jan 15, 2026 | 2026-01-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Encompass Health Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.